Population Pharmacokinetic Analysis Supports Initiation Treatment and Bridging from Sublingual Buprenorphine to Subcutaneous Administration of a Buprenorphine Depot (CAM2038) in the Treatment of Opioid Use Disorder

Overview

Journal Clin Pharmacokinet

Specialty Pharmacology

Date 2023 Aug 16

PMID 37584841

Authors

Marcus Bjornsson

Chayan Acharya

Kerstin Strandgarden

Fredrik Tiberg

Affiliations

Soon will be listed here.

Abstract

Background And Objective: In treating opioid use disorder (OUD), subcutaneous (SC) extended-release buprenorphine (BPN) depots, e.g., CAM2038, have been shown to provide smaller and less frequent fluctuations in BPN plasma concentrations and pharmacodynamic responses, improve outcomes, reduce treatment burden, and lower risks of misuse and diversion compared to daily sublingual (SL) BPN. This analysis characterized the pharmacokinetics (PK) of BPN following intravenous and SL administration, and administration of SC CAM2038 weekly and monthly.

Methods: Pharmacokinetic data from two Phase 1 and two Phase 2 trials in healthy participants and participants with OUD, respectively, were used to develop a population PK model using non-linear mixed effects modelling. The analysis included data from 252 participants and 10,658 BPN observations.

Results: The disposition of BPN was best described by a three-compartment model with first-order elimination, and absorption of SL BPN and SC CAM2038 weekly and monthly by dual parallel absorption pathways. Model diagnostics indicated good predictive performance of BPN concentrations. Buprenorphine plasma concentration-time profiles were simulated for treatment initiation, switching from SL BPN to CAM2038 weekly and monthly, and tapering after interrupting treatment with CAM2038. Simulations predicted CAM2038 weekly and monthly doses that provided BPN plasma maximum concentration (C) and trough concentration (C) values at steady state within those observed following SL BPN administration.

Conclusions: This population PK model supports the use of CAM2038 doses as individualized treatment for OUD across different treatment stages, including initiation, switching from SL BPN according to established dose conversion schedules, and tapering.

Trial Registrations: ISRCTN41550730 (05/19/2014), ISRCTN24987553 (07/29/2014), NCT02611752 (11/23/2015), NCT02710526 (03/16/2016).

Citing Articles

Outpatient Low-Dose Initiation of Buprenorphine for People Using Fentanyl.

Suen L, Chiang A, Jones B, Soran C, Geier M, Snyder H JAMA Netw Open. 2025; 8(1):e2456253.

PMID: 39853975 PMC: 11762237. DOI: 10.1001/jamanetworkopen.2024.56253.

References

Megarbane B, Marie N, Pirnay S, Borron S, Gueye P, Risede P . Buprenorphine is protective against the depressive effects of norbuprenorphine on ventilation. Toxicol Appl Pharmacol. 2005; 212(3):256-67. DOI: 10.1016/j.taap.2005.08.002. View

Webster L, Gudin J, Raffa R, Kuchera J, Rauck R, Fudin J . Understanding Buprenorphine for Use in Chronic Pain: Expert Opinion. Pain Med. 2020; 21(4):714-723. PMC: 7139205. DOI: 10.1093/pm/pnz356. View

Huestis M, Cone E, Pirnay S, Umbricht A, Preston K . Intravenous buprenorphine and norbuprenorphine pharmacokinetics in humans. Drug Alcohol Depend. 2012; 131(3):258-62. PMC: 3663890. DOI: 10.1016/j.drugalcdep.2012.11.014. View

Webster L, Hansen E, Cater J, Smith T . A Phase I Placebo-Controlled Trial Comparing the Effects of Buprenorphine Buccal Film and Oral Oxycodone Hydrochloride Administration on Respiratory Drive. Adv Ther. 2020; 37(11):4685-4696. PMC: 7547962. DOI: 10.1007/s12325-020-01481-0. View

Tompkins D, Smith M, Mintzer M, Campbell C, Strain E . A double blind, within subject comparison of spontaneous opioid withdrawal from buprenorphine versus morphine. J Pharmacol Exp Ther. 2013; 348(2):217-26. PMC: 3912547. DOI: 10.1124/jpet.113.209478. View

Gudin J, Fudin J . A Narrative Pharmacological Review of Buprenorphine: A Unique Opioid for the Treatment of Chronic Pain. Pain Ther. 2020; 9(1):41-54. PMC: 7203271. DOI: 10.1007/s40122-019-00143-6. View

Laffont C, Gomeni R, Heidbreder C, Jones 3rd J, Nasser A . Population Pharmacokinetic Modeling After Repeated Administrations of RBP-6000, a New, Subcutaneously Injectable, Long-Acting, Sustained-Release Formulation of Buprenorphine, for the Treatment of Opioid Use Disorder. J Clin Pharmacol. 2015; 56(7):806-15. DOI: 10.1002/jcph.665. View

Lindbom L, Ribbing J, Jonsson E . Perl-speaks-NONMEM (PsN)--a Perl module for NONMEM related programming. Comput Methods Programs Biomed. 2004; 75(2):85-94. DOI: 10.1016/j.cmpb.2003.11.003. View

Jonsson E, Karlsson M . Automated covariate model building within NONMEM. Pharm Res. 1998; 15(9):1463-8. DOI: 10.1023/a:1011970125687. View

10.

Dematteis M, Auriacombe M, DAgnone O, Somaini L, Szerman N, Littlewood R . Recommendations for buprenorphine and methadone therapy in opioid use disorder: a European consensus. Expert Opin Pharmacother. 2017; 18(18):1987-1999. DOI: 10.1080/14656566.2017.1409722. View

11.

Webster L, Rauck R . Atypical opioids and their effect on respiratory drive. J Opioid Manag. 2021; 17(7):109-118. DOI: 10.5055/jom.2021.0648. View

12.

Compton P, Ling W, Moody D, Chiang N . Pharmacokinetics, bioavailability and opioid effects of liquid versus tablet buprenorphine. Drug Alcohol Depend. 2005; 82(1):25-31. DOI: 10.1016/j.drugalcdep.2005.08.005. View

13.

Dahan A, Yassen A, Romberg R, Sarton E, Teppema L, Olofsen E . Buprenorphine induces ceiling in respiratory depression but not in analgesia. Br J Anaesth. 2006; 96(5):627-32. DOI: 10.1093/bja/ael051. View

14.

Lindbom L, Pihlgren P, Jonsson E, Jonsson N . PsN-Toolkit--a collection of computer intensive statistical methods for non-linear mixed effect modeling using NONMEM. Comput Methods Programs Biomed. 2005; 79(3):241-57. DOI: 10.1016/j.cmpb.2005.04.005. View

15.

Poliwoda S, Noor N, Jenkins J, Stark C, Steib M, Hasoon J . Buprenorphine and its formulations: a comprehensive review. Health Psychol Res. 2022; 10(3):37517. PMC: 9392838. DOI: 10.52965/001c.37517. View

16.

Walsh S, Comer S, Zdovc J, Sarr C, Bjornsson M, Strandgarden K . Pharmacokinetic-pharmacodynamic analysis of drug liking blockade by buprenorphine subcutaneous depot (CAM2038) in participants with opioid use disorder. Neuropsychopharmacology. 2024; 49(6):1050-1057. PMC: 11039630. DOI: 10.1038/s41386-023-01793-z. View

17.

Coe M, Lofwall M, Walsh S . Buprenorphine Pharmacology Review: Update on Transmucosal and Long-acting Formulations. J Addict Med. 2018; 13(2):93-103. PMC: 7442141. DOI: 10.1097/ADM.0000000000000457. View

18.

Walsh S, Comer S, Lofwall M, Vince B, Levy-Cooperman N, Kelsh D . Effect of Buprenorphine Weekly Depot (CAM2038) and Hydromorphone Blockade in Individuals With Opioid Use Disorder: A Randomized Clinical Trial. JAMA Psychiatry. 2017; 74(9):894-902. PMC: 5710238. DOI: 10.1001/jamapsychiatry.2017.1874. View

19.

White L, Hodge A, Vlok R, Hurtado G, Eastern K, Melhuish T . Efficacy and adverse effects of buprenorphine in acute pain management: systematic review and meta-analysis of randomised controlled trials. Br J Anaesth. 2018; 120(4):668-678. DOI: 10.1016/j.bja.2017.11.086. View

20.

Dahan A, Yassen A, Bijl H, Romberg R, Sarton E, Teppema L . Comparison of the respiratory effects of intravenous buprenorphine and fentanyl in humans and rats. Br J Anaesth. 2005; 94(6):825-34. DOI: 10.1093/bja/aei145. View